Awakn Life Sciences
Therapeutics for substance use and mental health disorders.
Awakn Life Sciences
Therapeutics for substance use and mental health disorders.
About Awakn
Awakn is a Clinical Stage Biotechnology Company Developing Therapeutics for Substance Use and Mental Health Disorders.
Awakn has a near-term focus on Alcohol Use Disorder (AUD), a condition affecting approximately 29[¹] million adults in the US and approximately 40 million [²,³,⁴,⁵,⁶] in the US and key European for which the current standard of care is inadequate.
Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercialising our R&D pipeline across multiple channels.
Therapeutic Development Pipeline
Addiction: The other pandemic
Approximately 51 million people in the US, UK, and EU big 4 markets, and 285 million people globally are affected by Alcohol Use Disorder.
Yet available treatments are poor. Just 10% of Alcohol Use Disorder sufferers in the US, UK, and big 4 European markets seek treatment1, and up to 75% of those people relapse within 12 months.
Because of the high prevalence of AUD and relatively low success rates for treatment the annual direct medical costs of AUD are significant: US$27-35bn in the US, US4bn in the UK, and US22bn in the EU big 41.
Our evidence-based approach
Awakn is developing a Medication-Assisted Treatments for Alcohol Use Disorder with potential to expand into other addiction in time.
Awakn’s MATs target the brain circuits that drive addiction. These circuits control the behavioural drivers of addiction.
This disruption allows the individual to escape from the repetitive addictive behaviours and thoughts, and in doing so engage with a psychotherapeutic process to enable lasting positive change.
Our therapies work in conjunction with our medicines enabling the patients to regain control over their lives and helping them to learn new more adaptive ways to respond to addictive urges, cravings and the underlying processes that drive them.
Our therapies are manualized and our protocols are condensed to ensure efficient use of healthcare resources, including people, time, and real estate.
Awakn partners with pharma companies, state bodies and research institutes R&D
References:
1. US Substance Abuse and Mental Health Services (SAMHSA), 2022 National Survey on Drug Use and Health
2. UK The National Institute for Health and Care Excellence (NICE) - Alcohol-use disorders diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence
3. Jahrbuch Sucht 2020 der Deutschen Hauptstelle für Suchtfragen
4. Inserm. Reducing the harm associated with alcohol consumption. Summary and recommendations. Collection Expertise collective. Montrouge: EDP Sciences, 2022.
5. Istituto Superiore di Sanità EpiCentro
6. Monografía. Alcohol 2021: Consumo y Consecuencias
Sign Up for Newsletter
MAIN OFFICE
Awakn Life Sciences Corp
301-217 Queen St. W
Toronto, Ontario M5V 0R2
Canada
© 2023 Awakn Life Sciences Corp | Privacy Policy | Disclaimer
